NCT02583893View on ClinicalTrials.gov

Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 7, 2015

Primary Completion Date

April 17, 2023

Study Completion Date

May 17, 2023

Conditions

Recurrent Adult Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaUntreated Adult Acute Myeloid Leukemia

Interventions

DRUG

Sirolimus

Given PO

DRUG

Mitoxantrone

Given IV

DRUG

Etoposide

Given IV

DRUG

Cytarabine

Given IV

Trial Locations (1)

19107

Thomas Jefferson University, Philadelphia

All Listed Sponsors

lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER

NCT02583893 - Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter